Clinlab Navigator

Isocitrate Dehydrogenase Mutations

Isocitrate dehydrogenase (IDH) normally catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate. IDH1 is a cytosolic enzyme that results in production of NADPH. It should not be confused with IDH2 which is an isoenzyme in the citric acid cycle that reduces NAD rather than NADP.  Mutations in IDH1 and IDH2 occur in a number of cancer types including ~20% of acute myeloid leukemias (AML).  IDH mutants gain the novel capacity to reduce α-ketoglutarate to D-2-hydroxyglutarate. D-2-hydroxyglutarate is known as an oncometabolite and its accumulation competitively inhibits α-ketoglutarate dependent enzyme activities including methlycytosine hydroxylation by members of the TET gene family and histone lysine demethylases belonging to the JMJD family. Such metabolic derangement promotes genetic hypermethylation and in the case of AML, leads to arrested differentiation of myeloid progenitors. 

IDH mutations have been identified in over 70% of lower-grade (II/III) diffuse gliomas and secondary glioblastoma. Assessment of IDH mutation status in central nervous system tumors assists in tumor classification and provide prognostic information for patients with diffuse gliomas.

Point mutations and small insertion/deletion mutations in the IDH1 and IDH2 genes are detected by next generation sequencing. Enasidenib and Ivosidenib are inhibitors of isocitrate dehydrogenase–1.

Updated Articles

Rubeola Antibodies…

Measles is caused by the rubeola virus, which is a single-stranded, enveloped RNA virus. Humans are the only natural hosts of measles virus. Measles virus normally grows in the cells that line the back of the throat and lungs. In the decade before…

New Articles

Jamestown Canyon…

Jamestown Canyon Virus is transmitted to people by infected mosquitos. Mosquitos become infected when they feed on infected deer. The virus is found throughout much of the United States, but Minnesota and Wisconsin have reported more than half of…

Blog

AD-Detect Test for…

Quest Diagnostics started offering its AD-Detect Test for Alzheimer Disease in 2023. Consumers can purchase the test for $399 plus a $13 physician service fee. The test utilizes liquid chromatography-tandem mass spectrometry to measure the ratio of…